Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Riley Children's Hospital - Indiana University School of Medicine
1867
mi
from 98109
Indianapolis, IN
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Riley Children's Hospital - Indiana University School of Medicine
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Childrens Center
2329
mi
from 98109
Baltimore, MD
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Childrens Center
2329
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Boston - Harvard Medical School
2485
mi
from 98109
Boston, MA
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Boston - Harvard Medical School
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Goryeb Children's Hospital/ Atlantic Health System
2377
mi
from 98109
Morristown, NJ
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Goryeb Children's Hospital/ Atlantic Health System
2377
mi
from 98109
Morristown, NJ
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
The Research Foundation of SUNY on behalf of the University at Buffalo
2109
mi
from 98109
Buffalo, NY
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
The Research Foundation of SUNY on behalf of the University at Buffalo
2109
mi
from 98109
Buffalo, NY
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Cohens (Schneider) Children's Hospital
2416
mi
from 98109
New Hyde Park, NY
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Cohens (Schneider) Children's Hospital
2416
mi
from 98109
New Hyde Park, NY
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
2009
mi
from 98109
Columbus, OH
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
2009
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
2373
mi
from 98109
Philadelphia, PA
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
2134
mi
from 98109
Pittsburgh, PA
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
2486
mi
from 98109
Providence, RI
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
2486
mi
from 98109
Providence, RI
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Monroe Carell Jr. Children's Hospital at Vanderbilt
1970
mi
from 98109
Nashville, TN
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Monroe Carell Jr. Children's Hospital at Vanderbilt
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Children's Medical Center
1676
mi
from 98109
Dallas, TX
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Children's Medical Center
1676
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
BCM Texas Children's Hospital - Houston
1892
mi
from 98109
Houston, TX
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
BCM Texas Children's Hospital - Houston
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Primary Children's Medical Center - University of Utah
703
mi
from 98109
Salt Lake City, UT
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Primary Children's Medical Center - University of Utah
703
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
IWK Health Centre
2752
mi
from 98109
Halifax,
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
IWK Health Centre
2752
mi
from 98109
Halifax,
Click here to add this to my saved trials
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital Comprehensive Cancer Center
2486
mi
from 98109
Providence, RI
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital Comprehensive Cancer Center
2486
mi
from 98109
Providence, RI
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2181
mi
from 98109
Decatur, GA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2181
mi
from 98109
Decatur, GA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1903
mi
from 98109
Ann Arbor, MI
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1450
mi
from 98109
Rochester, MN
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
147
mi
from 98109
Portland, OR
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
147
mi
from 98109
Portland, OR
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
681
mi
from 98109
San Francisco, CA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
681
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1005
mi
from 98109
Lafayette, CO
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1005
mi
from 98109
Lafayette, CO
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1025
mi
from 98109
Littleton, CO
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1025
mi
from 98109
Littleton, CO
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1016
mi
from 98109
Thornton, CO
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1016
mi
from 98109
Thornton, CO
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2431
mi
from 98109
Hamden, CT
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2431
mi
from 98109
Hamden, CT
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2449
mi
from 98109
Jacksonville, FL
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2449
mi
from 98109
Jacksonville, FL
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2730
mi
from 98109
Miami, FL
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2545
mi
from 98109
Winter Park, FL
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2545
mi
from 98109
Winter Park, FL
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2255
mi
from 98109
Macon, GA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2255
mi
from 98109
Macon, GA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1454
mi
from 98109
Topeka, KA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1454
mi
from 98109
Topeka, KA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2035
mi
from 98109
Baton Rouge, LA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2035
mi
from 98109
Baton Rouge, LA
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2316
mi
from 98109
Chevy Chase, MD
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2316
mi
from 98109
Chevy Chase, MD
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1922
mi
from 98109
Troy, MI
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1922
mi
from 98109
Troy, MI
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
2116
mi
from 98109
Cheektowaga, NY
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
2116
mi
from 98109
Cheektowaga, NY
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2283
mi
from 98109
Charlotte, NC
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2283
mi
from 98109
Charlotte, NC
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2241
mi
from 98109
Elkin, NC
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2241
mi
from 98109
Elkin, NC
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1877
mi
from 98109
Germantown, TN
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1877
mi
from 98109
Germantown, TN
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1790
mi
from 98109
San Antonio, TX
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1790
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1762
mi
from 98109
Tyler, TX
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1762
mi
from 98109
Tyler, TX
Click here to add this to my saved trials
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2285
mi
from 98109
Charlottesville, VA
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2285
mi
from 98109
Charlottesville, VA
Click here to add this to my saved trials